Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vialinin A is a natural p-terphenyl compound isolated from edible mushrooms, notably *Thelephora vialis* and *Thelephora terrestris*. It acts as a potent inhibitor of several deubiquitinating enzymes, most notably ubiquitin-specific peptidase 4 (USP4), USP5/isopeptidase T, and UCH-L1, with reported IC50 values of 1.5 μM (USP4), 5.9 μM (USP5/isopeptidase T), and 22.3 μM (UCH-L1)[1][2][3]. Vialinin A exhibits anti-inflammatory, antioxidant, anti-allergic, and antiangiogenic activities. It inhibits release of tumour necrosis factor alpha (TNF-α), interleukin 4, β-hexosaminidase, and monocyte chemotactic protein 1 in mast cells, and suppresses the production of angiogenic cytokines (e.g., angiopoietin-2, G-CSF, HB-EGF, HGF) in human vascular endothelial cells[1][3][4]. It blocks VEGF-induced neovascularization both in vitro and in vivo, primarily by inhibiting ROS generation and NF-κB nuclear translocation, and reduces inflammation and fibrosis by regulating the Rheb/mTOR signaling pathway[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vialinin a.